Primary liver cancer:: Worldwide incidence and trends
Primary liver cancer:: Worldwide incidence and trends
复制标题
DOI：
10.1053/j.gastro.2004.09.011
复制
发表时间：
2004-11-01
期刊：
影响因子：
29.4
通讯作者：
Cléries, R
中科院分区：
文献类型：
--
作者：
Bosch, FX;Ribes, J;Cléries, R
2000年的估计表明，肝癌仍然是全世界男性第五大常见恶性肿瘤，女性第八大常见恶性肿瘤。据估计，每年新病例数为564 000例，其中男性398 000例，女性166 000例。在高风险国家，肝癌可能在20岁之前发生，而在低风险国家，肝癌在50岁之前很少见。男性肝癌的发病率通常比女性高2至4倍。原发性肝癌的发病率在包括美国在内的几个发达国家正在增加，并且这种增加可能会持续几十年。这一趋势是与B和C型肝炎病毒感染有关的队列效应的结果，其发病率在20世纪50年代至80年代达到高峰。在一些发展中国家的某些地区，原发性肝癌的发病率有所下降，这可能是由于采用了B型肝炎病毒疫苗。原发性肝癌发病率的地理变异性在很大程度上是由B和C型肝炎病毒的分布和自然史解释的。这些感染的综合效应的归因风险估计占全球肝癌病例的80%以上。原发性肝癌是第一种很大程度上可以通过使用B型肝炎病毒疫苗以及对血液和血液制品进行B型和C型肝炎病毒筛查来预防的人类癌症。
Estimates from the year 2000 indicate that liver cancer remains the fifth most common malignancy in men and the eighth in women worldwide. The number of new cases is estimated to be 564,000 per year, including 398,000 in men and 166,000 in women. In high-risk countries, liver cancer can arise before the age of 20 years, whereas, in countries at low risk, liver cancer is rare before the age of 50 years. Rates of liver cancer in men are typically 2 to 4 times higher than in women. The incidence of primary liver cancer is increasing in several developed countries, including the United States, and the increase will likely continue for some decades. The trend is a result of a cohort effect related to infection with hepatitis B and C viruses, the incidence of which peaked in the 1950s to 1980s. In selected areas of some developing countries, the incidence of primary liver cancer has decreased, possibly as a result of the introduction of hepatitis B virus vaccine. The geographic variability in incidence of primary liver cancer is largely explained by the distribution and the natural history of the hepatitis B and C viruses. The attributable risk estimates for the combined effects of these infections account for well over 80% of liver cancer cases worldwide. Primary liver cancer is the first human cancer largely amenable to prevention using hepatitis B virus vaccines and screening of blood and blood products for hepatitis B and C viruses.